Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Monday, December 24 through Wednesday, December 26 inclusive. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 10.12.14 in Vol 3, No 4 (2014): Oct-Dec

This paper is in the following e-collection/theme issue:

Works citing "A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale"

According to Crossref, the following articles are citing this article (DOI 10.2196/resprot.3640):

(note that this is only a small subset of citations)

  1. Jiménez-Gallo D, Villegas-Romero I, Rodríguez-Mateos M, Linares-Barrios M. Treatment of Livedoid Vasculopathy With Rivaroxaban: A Potential Use of New Oral Anticoagulants for Dermatologists. Actas Dermo-Sifiliográficas (English Edition) 2018;109(3):278
    CrossRef
  2. Franco Marques G, Criado PR, Alves Batista Morita TC, Cajas García MS. The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban. International Journal of Dermatology 2018;57(6):732
    CrossRef
  3. Jiménez-Gallo D, Villegas-Romero I, Rodríguez-Mateos M, Linares-Barrios M. Vasculopatía livedoide tratada con rivaroxabán. Potenciales usos de los nuevos anticoagulantes orales para el dermatólogo. Actas Dermo-Sifiliográficas 2018;109(3):278
    CrossRef
  4. Renner R, Dissemond J, Goerge T, Hoff N, Kröger K, Erfurt-Berge C. Analysis of the German DRG data for livedoid vasculopathy and calciphylaxis. Journal of the European Academy of Dermatology and Venereology 2017;31(11):1884
    CrossRef
  5. Nakayama T, Mizutani K, Hanamura I, Kato H, Takami A, Takeshita K, Watanabe D. Livedoid vasculopathy and popliteal artery occlusion in a patient with protein S deficiency. The Journal of Dermatology 2017;44(2):198
    CrossRef
  6. Lee JM, Kim I. Case series of recalcitrant livedoid vasculopathy treated with rivaroxaban. Clinical and Experimental Dermatology 2016;41(5):559
    CrossRef
  7. Weishaupt C, Strölin A, Kahle B, Kreuter A, Schneider SW, Gerss J, Eveslage M, Drabik A, Goerge T. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. The Lancet Haematology 2016;3(2):e72
    CrossRef
  8. Evans JM, Jensen JD, Sami N. Successful treatment of livedoid vasculopathy with rivaroxaban. JAAD Case Reports 2015;1(6):340
    CrossRef